HeartAsureLogo2_540x85.jpg



Join the HeartAsure movement by adding Abbott's High-Sensitive Troponin-I Cardiac specific blood test to your patient's health check. And help change lives.
 

cardiovascular risk:
a global challenge

 
Cardiovascular Disease Icon
Cardiovascular disease (CVD)

#1 Cause 

of death globally2
 
CVD Cases Icon

422.7M

CVD Cases around the world 20153
 
Projected Deaths from CVD Icon

31.7%

projected deaths from cvd by 20304

YOU WANT THE BEST Cardiovascular Risk Stratification FOR YOUR PATIENTS

While there are a variety of CV risk prediction models currently available, no other test is specific to the heart. These other models, which take into consideration the presence of CV risk factors, are indirect methods that pose challenges due to their focus on age and ethnicity, their applicability only in certain populations, and their ability to measure a limited number of CV outcomes.5,6 Since Troponin-I is specific to the heart, it can more accurately categorize patients' risk, in conjunction with other clinical and diagnostic findings — before they experience a cardiovascular event.7,8

prevention is better than a cure1
IdentifyingRisk-icon-82x82.jpg

Identifying CV risk factors, and doing so early, are an important part of prevention. Abbott's High Sensitive Troponin-I (hsTnI) is a cardiac-specific blood test, and the first CE marked cardiac-specific biomarker for risk stratification of the apparently healthy population. 9

Blood Test Icon

Abbott's hsTnI blood test more accurately categorizes a patient into low, moderate, or elevated risk categories when used in conjunction with clinical and diagnostic findings.9 Through this early cardiac risk identification model, long-term lifestyle changes and targeted treatments can be recommended to patients before a cardiac incident takes place.16 This helps labs and the physician empower patients to take control of their well-being by making healthy choices.

 

 

more accurately identify your patients'
risk of a future caridac event — 

EVEN IN THOSE WITHOUT
SIGNS OR SYMPTOMS, with Troponin-I

Blood tests measuring troponin have long been used in the ER - after a cardiac event has occured.10 By simply adding the Abbott hsTnl blood test to your patients' health check in conjunction with other clinical and diagnostic findings, it is now possible to more accurately identify and predict a patient's risk of future cardiac events even when no signs or symptoms of cardiac disease are present.9


  Talk to Abbott

 

HeartAsure - Risk Stratification Logo

the cardiovascular disease prevention movement

It is important for clinicians to be able to assess CV risk in asymptomatic patients and with sufficient accuracy. Abbott created the HeartAsure campaign to inform and educate physicians and laboratorians about why Abbott's hsTnI blood test needs to be a vital part of standard wellness checks to help prevent CVDs.

Abbott's Troponin-I is the first CE marked biomarker that aids in predicting future cardiac events in asymptomatic individuals through the power of cardiac specificity in conjuction with other clinical and diagnostic findings. By doing so Troponin-I can help more accurately stratify the risk of future cardiovascular disease even in patients who may appear healthy by definitively identifying levels of troponin in the blood.8

 


 

 
 
Join the HeartAsure movement by adding Abbott's
High-Sensitive Troponin-I Cardiac specific blood test to your patient's health check. And help change lives.
 
 
 
 
 
The following cut-off points may be used to aid in stratifying the risk of cardiovascular disease in asymptomatic individuals: 8,9  High Sensitive Troponin Chart

a cardiac-specific and more accurate early detection cardiovascular risk assessment tool

Abbott's hsTnI test helps identify a patient with an elevated risk of a future cardiac event with more accuracy.9,11-14 With your guidance and medical recommendations, patients can better manage their health. This tool enables physicians and labs to provide improved recommendations for preventative healthcare to their patients.

 
                                                                                                                                                                                                                                     



what if there was a direct
signal coming from
the heart itself?

- Dr. Gillian Murtagh

 

 
 
 
                                                                                                                                                                                                              

how does hstnI Cardiac risk stratification compare with current tools?

Current risk-stratification tools like Framingham, SCORE, and Lipid profile are not cardiac-specific and can be overly influenced by age. Abbott's hsTnI risk stratification blood test contains the protein Troponin-I, which is specific to the heart. This means it can more accurately categorize patients' risk when used in conjunction with clinical and diagnostic findings.9,11-14

 

Troponin-I-Realeased-FromHeart-Diagram-450x240.jpg
Early Detection Icon

Early detection to more accurately evaluate risk of future cardiac events, in conjunction with other clinical and diagnostic findings.9

Greater Accuracy Icon

Greater accuracy in identifying lower-risk patients, which may avoid unnecessary testing, treatments, and potential side effects.9

Reduce Cost Icon

Potential to reduce the growing cost burden to the healthcare system by appropriately recategorizing at-risk patients.9

Resistant Icon

Abbott's hsTnI is not impacted by biotin interference.15 

Customer Testimonials

Dr. Winfried März, University Professor at the Medical University of Graz, shares information about the targeted use of Troponin-I as a biomarker to identify potential cardiac risks at an early stage in asymptomatic patients.

View Dr. März's Testimonial

Cardiologists Professor Dr. Christoph Liebetrau and Associate Professor Dr. Till Keller from the Cardiac Center in Bad Nauheim, Germany discuss the significance of cardiac risk stratification with Troponin-I and possible areas of application.

View Dr. Liebetrau Testimonial
   
Resources

 

HCP-iPad_220x110.jpg
physician pathway

Read The Pathway 
Patient-HCP_220x110.jpg
Risk Stratification brochure
Read The Brochure 
Troponin_220x110.jpg
publication
summaries
Read the Publication
HCPs-gather_220x110.jpg
physician Resource

Read the Resource 

 

 

identify. predict. act.

 

 

PhysPathway-529x529.jpg

 

 

How Can You help prevent cardiovascular disease?

By offering a cardiac-specific biomarker that is a direct signal from the heart, physicians and labs can help identify and predict the risk of future cardiac events, in conjunction with other clinical and diagnostic findings.9,11-14

Patients can then become more educated about their health, and are able to make more informed decisions and choices in striving for better heart health.

join the heartasure movement

ADD abbott's high sensitive
troponin-i cardiac-specific blood
test to your patients' health check.

Together, we can create a cardiac movement toward prevention.
And help change lives.
Explore 


Troponin_300x200.jpg

Understand the Value of Troponin 

Explore how High Sensitive Troponin may enable easier management of patients with suspect AMI. 

Learn more About Troponin

Cardiac-Hero_300x200.jpg

Cardiac Assays

Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.

View Cardiac Solutions

building-windows300x200.jpg

Visit the Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Visit the Knowledge Center 

References
  1. Lüscher, T. Prevention is better than cure: the new ESC Guidelines. Eur Heart J. 2016;37:2291-2293
  2. Heart Disease, Stroke and Research Statistics At-a-Glance – American Heart Association.    
  3. Laslett LJ, et al.  J Am Coll Cardiol. 2012 Dec 25;60(25 Suppl):S1-49 
  4. World Health Organization Fact sheet. Cardiovascular diseases https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)  
  5. DeFilippis AP, et. al Ann Intern Med. 2015;162(4):266-275.
  6. Garg N, et al. Indian Heart J. 2017;69(4):458-463. doi:10.1016/j.ihj.2017.01.015.
  7. Thygesen K, et al. Circulation. 2012;126(16):2020-2035. 
  8. ARCHITECT STAT High Sensitive Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories; 2018. G97079R01.
  9. Sigurdardottir FD, et al. 2018;121(8):949-955. 

  1. Anthony K. Healthline. https://www.healthline.com/health/troponin-levels. Published February 2018. Accessed June 1, 2020 
  2. Ford I, et al. J Am Coll Cardiol. 2016 Dec 27;68(25):2719–2728.
  3. Blankenberg S, et al. Eur Heart J. 2016 Aug 7;37(30):2428–2437.
  4. Everett BM, et al. Circulation. 2015 May 26;131(21):1851–1860.
  5. Omland T, et al. Clin Chem. 2015 Apr;61 (4):646–656.
  6. Trambas C, et al. Ann Clin Biochem. 2017;55(2):216-226. 
  7. Piepoli, et al, EHJ (2016) 37, 2315–2381

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No